Antibe Therapeutics Stock Price

TSX:ATECA$15.6mPharmaceuticals & Biotech

ATE Share Price Performance

ATE Community Fair Values

Your Fair Value
CA$
Current Price
CA$0.29n/aintrinsic discount
Growth estimate over
Annual revenue growth rate
%/yr
Decrease
Increase
Advanced

View all narratives

Recent ATE News & Updates

Antibe Therapeutics Inc. Competitors

View more competitors

Antibe Therapeutics Inc. Key Details

Last Reported Earnings

Dec 31, 2023

Yearly revenue growth

67.04%

Earnings per share (EPS): -0.34
Gross Margin: 0%
Net Profit Margin: 0%
Debt/Equity Ratio: 0%

View full report ›

Canadian Market Performance

7 Days: 0.3%
3 Months: 8.1%
1 Year: 19.2%
Year to Date: 6.6%

In the last week, the market has stayed flat, however the Energy sector stood out, gaining 3.3%. Meanwhile, the market is actually up 19% over the past year. Earnings are forecast to grow by 12% annually. Market details ›

🚀 Finding Moonshots in the Space Race

Richard Bowman

June 2025

The Space industry has a massive runway ahead of it, so it’s worth getting to know it if you are a long-term investor. We figured now would be a great time to check in on the industry!

Last Week

Antibe Therapeutics Stock Price

ATE Share Price Performance

ATE Community Fair Values

Recent ATE News & Updates

Antibe Therapeutics Inc. Announces Board Resignations

Antibe Therapeutics Inc. Announces Board Resignations

New major risk - Market cap size

Nuance Pharma Limited Commences Legal Action Against Antibe Therapeutics Inc. in the Ontario Superior Court Legal Action

Price target decreased by 14% to CA$1.50

New minor risk - Profitability

Antibe Therapeutics Inc. Competitors

🚀 Finding Moonshots in the Space Race

🎢 Opportunities In The Turbulent Transition To Greener Energy